ZKSCAN5 transcriptional regulation of APOC1 modulates ferroptosis via PI3K/AKT/SREBP2/SLC1A5 axis.

IF 7.5 2区 医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL
Yongbo Liu, Zihao Qi, Shuo Yang, Yanze Li, Jia Guo
{"title":"ZKSCAN5 transcriptional regulation of APOC1 modulates ferroptosis via PI3K/AKT/SREBP2/SLC1A5 axis.","authors":"Yongbo Liu, Zihao Qi, Shuo Yang, Yanze Li, Jia Guo","doi":"10.1186/s12967-025-07092-z","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Prostate cancer is a great substantial health challenge among the cancer type with a high incidence and serving as the main cause of cancer-related deaths in men. Apolipoprotein C1 encodes a member of the apolipoprotein C family. The APOC1 has been confirmed as an oncogene of prostate cancer. However, the mechanism of how the APOC1 protein influence remains to be elucidated.</p><p><strong>Methods: </strong>The expression of APOC1 was detected in both prostate cancer tissues and prostate cancer cell lines. The APOC1 knockdown and overexpression cell models were created. The effect of APOC1 on prostate cancer cell proliferation,metastasis, EMT and ferroptosis were explored by colony formation, wound healing,transwell assays, CCK-8 and western blotting in vitro and subcutaneous tumor formation in nude mice. Furthermore, the mechanism of how APOC1 inhibits ferroptosis in prostate cancer through PI3K/AKT/SREBP2/SLC1A5 was detected. Meanwhile, the interaction of APOC1 and ZKSCAN5 (zinc finger with KRAB and SCAN domains 5) was determined using Chromatin Immunoprecipitation (ChIP).</p><p><strong>Results: </strong>APOC1 expression was significantly upregulated in prostate cancer tissues and cell lines. Genetic silencing of APOC1 by shRNA demostrated potent tumor-suppressive effects, markedly inhibiting cell proliferation, metastasis and EMT, while concurrently enhancing ferroptosis rates. Then, APOC1 was shown to modulate cholesterol homeostasis via the PI3K/AKT/SREBP2/SLC1A5 signaling cascade, thereby influencing ferroptosis susceptibility in prostate cancer cells. Mechanistically, ZKSCAN5 was identified as a transcriptional repressor of APOC1 through direct promoter binding. Notably, the anti-ferroptosis function of APOC1 was mediated through SREBP2-dependent transcriptional regulation, with Cut&Tag (Cleavage Under Targets and Tagmentation) confirming SREBP-2's direct binding to the SLC1A5 promoter.</p><p><strong>Conclusion: </strong>In prostate cancer, APOC1 regulates ferroptosis via PI3K/AKT/SREBP2/SLC1A5 axis, meanwhile ZKSCAN5 negatively regulates the expression of APOC1.</p>","PeriodicalId":17458,"journal":{"name":"Journal of Translational Medicine","volume":"23 1","pages":"1020"},"PeriodicalIF":7.5000,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12486724/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Translational Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12967-025-07092-z","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Prostate cancer is a great substantial health challenge among the cancer type with a high incidence and serving as the main cause of cancer-related deaths in men. Apolipoprotein C1 encodes a member of the apolipoprotein C family. The APOC1 has been confirmed as an oncogene of prostate cancer. However, the mechanism of how the APOC1 protein influence remains to be elucidated.

Methods: The expression of APOC1 was detected in both prostate cancer tissues and prostate cancer cell lines. The APOC1 knockdown and overexpression cell models were created. The effect of APOC1 on prostate cancer cell proliferation,metastasis, EMT and ferroptosis were explored by colony formation, wound healing,transwell assays, CCK-8 and western blotting in vitro and subcutaneous tumor formation in nude mice. Furthermore, the mechanism of how APOC1 inhibits ferroptosis in prostate cancer through PI3K/AKT/SREBP2/SLC1A5 was detected. Meanwhile, the interaction of APOC1 and ZKSCAN5 (zinc finger with KRAB and SCAN domains 5) was determined using Chromatin Immunoprecipitation (ChIP).

Results: APOC1 expression was significantly upregulated in prostate cancer tissues and cell lines. Genetic silencing of APOC1 by shRNA demostrated potent tumor-suppressive effects, markedly inhibiting cell proliferation, metastasis and EMT, while concurrently enhancing ferroptosis rates. Then, APOC1 was shown to modulate cholesterol homeostasis via the PI3K/AKT/SREBP2/SLC1A5 signaling cascade, thereby influencing ferroptosis susceptibility in prostate cancer cells. Mechanistically, ZKSCAN5 was identified as a transcriptional repressor of APOC1 through direct promoter binding. Notably, the anti-ferroptosis function of APOC1 was mediated through SREBP2-dependent transcriptional regulation, with Cut&Tag (Cleavage Under Targets and Tagmentation) confirming SREBP-2's direct binding to the SLC1A5 promoter.

Conclusion: In prostate cancer, APOC1 regulates ferroptosis via PI3K/AKT/SREBP2/SLC1A5 axis, meanwhile ZKSCAN5 negatively regulates the expression of APOC1.

ZKSCAN5转录调控APOC1通过PI3K/AKT/SREBP2/SLC1A5轴调控铁死亡。
背景:前列腺癌是男性癌症相关死亡的主要原因,是发病率高、对健康构成重大挑战的癌症类型之一。载脂蛋白C1编码载脂蛋白C家族的一个成员。apo1已被证实是前列腺癌的致癌基因。然而,APOC1蛋白如何影响的机制仍有待阐明。方法:检测APOC1在前列腺癌组织和前列腺癌细胞系中的表达。建立APOC1敲低和过表达细胞模型。通过集落形成、创面愈合、transwell实验、体外CCK-8和western blotting及裸鼠皮下肿瘤形成等方法探讨APOC1对前列腺癌细胞增殖、转移、EMT和铁下垂的影响。进一步检测APOC1通过PI3K/AKT/SREBP2/SLC1A5抑制前列腺癌铁下垂的机制。同时,利用染色质免疫沉淀(ChIP)测定APOC1和ZKSCAN5(锌指与KRAB和SCAN结构域5)的相互作用。结果:APOC1在前列腺癌组织和细胞系中的表达明显上调。shRNA基因沉默APOC1显示出强大的肿瘤抑制作用,显著抑制细胞增殖、转移和EMT,同时提高铁下垂率。随后,APOC1被证明通过PI3K/AKT/SREBP2/SLC1A5信号级联调节胆固醇稳态,从而影响前列腺癌细胞铁凋亡的易感性。在机制上,ZKSCAN5通过直接启动子结合被鉴定为APOC1的转录抑制因子。值得注意的是,APOC1的抗铁凋亡功能是通过srebp2依赖的转录调控介导的,Cut&Tag(裂解靶下和标记)证实了srebp2直接结合SLC1A5启动子。结论:在前列腺癌中,APOC1通过PI3K/AKT/SREBP2/SLC1A5轴调控铁凋亡,同时ZKSCAN5负向调控APOC1的表达。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Translational Medicine
Journal of Translational Medicine 医学-医学:研究与实验
CiteScore
10.00
自引率
1.40%
发文量
537
审稿时长
1 months
期刊介绍: The Journal of Translational Medicine is an open-access journal that publishes articles focusing on information derived from human experimentation to enhance communication between basic and clinical science. It covers all areas of translational medicine.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信